Hodgkin lymphoma is a rare B-cell malignant neoplasm affecting approximately 9000 new
patients annually. This disease represents approximately 11% of all lymphomas seen in the …

Abstract Disease Overview Hodgkin lymphoma (HL) is an uncommon B‐cell lymphoid
malignancy affecting 8500 new patients annually and representing approximately 10.2% of …

Background Combined-modality treatment consisting of chemotherapy and consolidation
radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin …

Background Whether it is possible to reduce the intensity of treatment in early (stage I or II)
Hodgkin's lymphoma with a favorable prognosis remains unclear. We therefore conducted a …

Purpose Combined-modality treatment consisting of four to six cycles of chemotherapy
followed by involved-field radiotherapy (IFRT) is the standard of care for patients with early …

Purpose In patients with early unfavorable Hodgkin's lymphoma (HL), combined modality
treatment with four cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) …

Background Treatment of early-stage Hodgkin's disease is usually tailored in line with
prognostic factors that allow for reductions in the amount of chemotherapy and extent of …

Purpose Hodgkin's lymphoma (HL) survivors are known to be at substantially increased risk
of solid cancers (SC). However, no investigation has used multivariate modeling to estimate …

BACKGROUND AND PURPOSE: To describe new concepts for radiation fields in patients
with early stage Hodgkin lymphoma treated with a combined modality. PATIENTS AND …

Management of Hodgkin's lymphoma continues to develop. Outcomes for patients with
favourable-risk, early-stage disease are excellent, and serial reductions in intensity of …